Immunotherapy Stream

Developing Novel, Targeted Immunotherapies for Cancer and Immune Disorders 

The Immunotherapy stream highlights the most exciting tools, technologies and engineering strategies driving the development of cellular and non-cellular immunotherapies for cancer and immune disorders. Part One examines recent breakthroughs in T cell biology, protein engineering and novel IO targets, plus new approaches for improving immunotherapy efficacy and safety. Part Two discusses the latest developments in cellular immunotherapy such as CAR Ts, TCRs, NKs, and TILs, including innovations in allogenic cellular therapy, gene editing and targeting, all supported by in-depth case studies and clinical data. 

Conferences Include:

May 11-12

Improving Immunotherapy Efficacy and Safety

May 12-13

CAR Ts, TCRs and TILs

Recommended Short Course:

SC1: CAR T Cell Therapy from A-Z

Instructor: Tara Arvedson, PhD, Executive Director, Oncology Research, Amgen, Inc.

Keynote Speakers:

Adrian Bot, PhD, Vice President and Global Head, Translational Medicine, Kite Pharma, a Gilead Company

David L. Porter, MD, Professor & Director Cell Therapy & Transplantation, Hematology & Oncology, University of Pennsylvania

Laszlo G. Radvanyi, PhD, President & Scientific Director, Ontario Institute for Cancer Research

Cameron J. Turtle, MBBS PhD, Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Centre